strong>Abbvie Inc., of North Chicago, said it entered an exclusive worldwide license agreement with C2N Diagnostics, of St. Louis, to develop and commercialize a portfolio of anti-tau antibodies for the treatment of Alzheimer's disease and other neurological disorders. Read More
Bioinvent International AB, of Lund, Sweden, completed a strategic analysis of its ICAM-1-targeted phase II antibody, BI-505, to seek input from thought leaders with respect to the development program. Read More
Galena Biopharma Inc., of Portland, Ore., closed a public offering of about 24.4 million shares of common stock and warrants to purchase an aggregate of nearly 12.2 million shares of common stock at an exercise price of $2.08 per share. Read More
The Biotechnology Industry Organization (BIO) released an independent study documenting the impact of academia-industry technology transfer to the U.S. economy. Titled "The Economic Contribution of University/Nonprofit Inventions in the United States: 1996-2013," the report tracks academia-industry patent licensing over that 18-year period, estimating that it bolstered U.S. gross industry output by up to $1.18 trillion, U.S. gross domestic product by up to $518 billion and supported about 3.8 million U.S. jobs. Read More
HONG KONG – Preoperative atrial natriuretic peptide (ANP) improved survival in lung cancer patients undergoing surgery and appeared to prevent cancer metastasis through prevention of vascular endothelial inflammation and adhesion in mice, Japanese researchers reported in the March 16, 2015, early edition of the Proceedings of the National Academy of Sciences. Read More
SHANGHAI – In the almost two years since Chinese police said they were investigating Glaxosmithkline plc for corruption, the industry here has seen compliance go from a mid-level priority, second to meeting ambitious sales targets, to a board-level issue directly concerning senior management teams and those legally responsible for the business. Read More
LONDON – It was a love-in to celebrate the 20th anniversary of the EMA and the start of centralized approvals across Europe, but Elias Zerhouni, president of global R&D at Sanofi SA, pulled few punches in his keynote address, calling for greater consistency, increased speed and a more science-based approach to regulation. Read More
DUBLIN – Lyxumia (lixisenatide), the glucagon-like peptide 1 (GLP-1) agonist, which Zealand Pharma A/S out-licensed to Sanofi SA, is on track for a third-quarter new drug application (NDA) filing, following a cardiovascular safety study in which the drug had a similar profile to placebo. Read More
Less than a year after joining Nasdaq through a merger, Assembly Biosciences Inc. is tapping keen interest in the science behind its potentially curative preclinical hepatitis B virus (HBV) and Clostridium difficile-associated diarrhea (CDAD) programs through a $75 million public offering that will carry it well into 2017 or beyond. Read More
If anyone still doubted the power of chimeric antigen receptor T-cell (CAR T) technology to propel pipelines and stock prices, they needed look no further than the cross-country deal between Coronado Biosciences Inc. and the City of Hope to advance a portfolio of assets in newly created Mustang Therapeutics Inc. Read More
Pfizer Inc., of New York, said the findings from its Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA) have been published in the March 19, 2015, issue of The New England Journal of Medicine. Read More
